Better Buy: Johnson & Johnson vs. AbbVie
It's been a neck-and-neck race between Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) stocks so far in 2017. The two healthcare stocks are up by nearly identical levels year to date. And that's despite revenue headwinds for J&J and strong sales growth for AbbVie.
Which of these two stocks is the better buy right now? The primary criteria for investors to grade the companies on include current products, growth prospects, dividend strength, and valuation. Here's how Johnson & Johnson and AbbVie compare.
Image source: Getty Images.
Source: Fool.com
Johnson & Johnson Aktie
234,65 €
0,17 %
Die Johnson & Johnson Aktie ist ein klarer Community-Favorit: Nur Buy-Einschätzungen, keine Sell-Einschätzungen.
Für Johnson & Johnson ergibt sich ein negatives Potenzial von -1.13%, obwohl das Kursziel von 232 € unter 234.65 € liegt.
